Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alcohol Drinking | 18 | 2017 | 3957 | 2.710 |
Why?
|
Alcoholic Beverages | 6 | 2016 | 265 | 1.770 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2022 | 256 | 1.310 |
Why?
|
Alcohol-Related Disorders | 4 | 2015 | 234 | 1.140 |
Why?
|
Australia | 13 | 2017 | 1167 | 1.080 |
Why?
|
Drug Users | 3 | 2014 | 131 | 1.010 |
Why?
|
Leisure Activities | 4 | 2017 | 311 | 1.000 |
Why?
|
Harm Reduction | 3 | 2015 | 129 | 0.870 |
Why?
|
Splenic Neoplasms | 1 | 2021 | 100 | 0.750 |
Why?
|
Automobile Driving | 2 | 2016 | 431 | 0.730 |
Why?
|
Self Efficacy | 2 | 2014 | 610 | 0.730 |
Why?
|
Food Industry | 2 | 2011 | 68 | 0.720 |
Why?
|
Cities | 3 | 2017 | 511 | 0.700 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 180 | 0.690 |
Why?
|
Risk-Taking | 3 | 2014 | 986 | 0.660 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2023 | 2948 | 0.640 |
Why?
|
Violence | 2 | 2015 | 908 | 0.630 |
Why?
|
Sports | 3 | 2013 | 686 | 0.620 |
Why?
|
Adolescent Behavior | 3 | 2015 | 1150 | 0.600 |
Why?
|
Leukemia | 4 | 2022 | 1507 | 0.580 |
Why?
|
Alcoholic Intoxication | 2 | 2016 | 188 | 0.530 |
Why?
|
Crime | 2 | 2014 | 215 | 0.530 |
Why?
|
Licensure | 1 | 2016 | 124 | 0.530 |
Why?
|
Hematopoiesis | 6 | 2023 | 2066 | 0.520 |
Why?
|
Conflict of Interest | 2 | 2011 | 542 | 0.520 |
Why?
|
Juvenile Delinquency | 1 | 2015 | 125 | 0.510 |
Why?
|
DNA Damage | 2 | 2023 | 2423 | 0.490 |
Why?
|
Marketing | 3 | 2012 | 208 | 0.490 |
Why?
|
Internet | 4 | 2014 | 3062 | 0.480 |
Why?
|
Ascorbic Acid | 1 | 2017 | 647 | 0.480 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1379 | 0.470 |
Why?
|
Aggression | 3 | 2013 | 753 | 0.460 |
Why?
|
Industry | 2 | 2012 | 365 | 0.450 |
Why?
|
Substance Abuse Detection | 1 | 2015 | 283 | 0.450 |
Why?
|
Integrin beta3 | 1 | 2013 | 122 | 0.440 |
Why?
|
Mutation | 11 | 2023 | 29717 | 0.440 |
Why?
|
Food Labeling | 1 | 2015 | 178 | 0.430 |
Why?
|
Substance-Related Disorders | 5 | 2017 | 4250 | 0.410 |
Why?
|
Public Relations | 1 | 2011 | 22 | 0.410 |
Why?
|
Lymphoma | 1 | 2021 | 1873 | 0.410 |
Why?
|
Awareness | 1 | 2015 | 639 | 0.390 |
Why?
|
Neoplastic Stem Cells | 5 | 2018 | 1376 | 0.380 |
Why?
|
Wine | 1 | 2011 | 165 | 0.380 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 3038 | 0.380 |
Why?
|
Beer | 1 | 2010 | 127 | 0.360 |
Why?
|
Dioxygenases | 2 | 2022 | 316 | 0.350 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1596 | 0.350 |
Why?
|
Personal Satisfaction | 1 | 2014 | 634 | 0.340 |
Why?
|
Health Status | 2 | 2014 | 4030 | 0.330 |
Why?
|
Health Education | 1 | 2015 | 1053 | 0.330 |
Why?
|
Rural Population | 3 | 2014 | 2207 | 0.330 |
Why?
|
Social Responsibility | 1 | 2011 | 389 | 0.320 |
Why?
|
Athletes | 2 | 2012 | 1092 | 0.310 |
Why?
|
Universities | 2 | 2012 | 953 | 0.310 |
Why?
|
Financial Management | 1 | 2009 | 160 | 0.310 |
Why?
|
Groin | 1 | 2007 | 102 | 0.300 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2019 | 3497 | 0.300 |
Why?
|
Breast Neoplasms | 3 | 2023 | 20774 | 0.300 |
Why?
|
Data Collection | 3 | 2014 | 3339 | 0.300 |
Why?
|
RNA Interference | 3 | 2016 | 2890 | 0.300 |
Why?
|
Behavior, Addictive | 2 | 2011 | 460 | 0.290 |
Why?
|
Femoral Vein | 1 | 2007 | 159 | 0.290 |
Why?
|
Wounds and Injuries | 2 | 2017 | 2400 | 0.290 |
Why?
|
Humans | 58 | 2023 | 742088 | 0.270 |
Why?
|
Social Behavior | 1 | 2012 | 1128 | 0.270 |
Why?
|
Urban Population | 1 | 2014 | 2018 | 0.270 |
Why?
|
Thalidomide | 2 | 2022 | 888 | 0.270 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1364 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5171 | 0.240 |
Why?
|
Health Surveys | 2 | 2014 | 4030 | 0.230 |
Why?
|
Substance Abuse, Intravenous | 1 | 2007 | 522 | 0.220 |
Why?
|
Peptide Termination Factors | 1 | 2022 | 55 | 0.210 |
Why?
|
Allosteric Site | 1 | 2022 | 103 | 0.210 |
Why?
|
Hematopoietic Stem Cells | 6 | 2022 | 3381 | 0.210 |
Why?
|
Oncogenes | 2 | 2022 | 1263 | 0.200 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2023 | 430 | 0.200 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6347 | 0.200 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2022 | 310 | 0.190 |
Why?
|
Quality of Life | 2 | 2014 | 12730 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 193 | 0.180 |
Why?
|
Young Adult | 12 | 2022 | 56350 | 0.180 |
Why?
|
Dipeptides | 1 | 2022 | 409 | 0.180 |
Why?
|
Polymerization | 1 | 2020 | 163 | 0.180 |
Why?
|
Female | 25 | 2023 | 379592 | 0.180 |
Why?
|
Hematologic Neoplasms | 3 | 2022 | 1820 | 0.180 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 212 | 0.170 |
Why?
|
Taxes | 2 | 2011 | 221 | 0.170 |
Why?
|
Mice | 13 | 2023 | 81045 | 0.170 |
Why?
|
Ferritins | 1 | 2022 | 590 | 0.170 |
Why?
|
Adult | 17 | 2023 | 213712 | 0.170 |
Why?
|
Patient-Centered Care | 1 | 2009 | 1436 | 0.160 |
Why?
|
Sampling Studies | 2 | 2010 | 623 | 0.160 |
Why?
|
Aminopyridines | 1 | 2022 | 541 | 0.160 |
Why?
|
Serine | 1 | 2022 | 828 | 0.160 |
Why?
|
N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2010 | 65 | 0.160 |
Why?
|
Cell Cycle | 2 | 2023 | 2964 | 0.160 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2023 | 451 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13019 | 0.160 |
Why?
|
Adolescent | 11 | 2022 | 85649 | 0.160 |
Why?
|
Male | 22 | 2022 | 349538 | 0.150 |
Why?
|
Health Policy | 1 | 2010 | 2657 | 0.150 |
Why?
|
Victoria | 2 | 2014 | 67 | 0.150 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1866 | 0.150 |
Why?
|
Public Policy | 2 | 2011 | 572 | 0.140 |
Why?
|
Odds Ratio | 2 | 2022 | 9846 | 0.140 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2023 | 1860 | 0.140 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 3133 | 0.140 |
Why?
|
Middle Aged | 13 | 2022 | 213127 | 0.140 |
Why?
|
Germ Cells | 1 | 2020 | 628 | 0.140 |
Why?
|
CLOCK Proteins | 1 | 2016 | 87 | 0.130 |
Why?
|
Gout | 1 | 2022 | 556 | 0.130 |
Why?
|
Neoplasms | 2 | 2022 | 21596 | 0.130 |
Why?
|
ARNTL Transcription Factors | 1 | 2016 | 98 | 0.130 |
Why?
|
Self Report | 2 | 2017 | 3548 | 0.130 |
Why?
|
Age Factors | 3 | 2016 | 18355 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1052 | 0.120 |
Why?
|
Base Sequence | 2 | 2018 | 12797 | 0.120 |
Why?
|
Selection, Genetic | 1 | 2019 | 914 | 0.120 |
Why?
|
Research Design | 1 | 2010 | 5979 | 0.120 |
Why?
|
Casein Kinase Ialpha | 1 | 2014 | 26 | 0.120 |
Why?
|
Animals | 14 | 2023 | 168561 | 0.120 |
Why?
|
Social Control, Formal | 1 | 2014 | 110 | 0.120 |
Why?
|
Protein Conformation | 1 | 2022 | 4013 | 0.120 |
Why?
|
Health Personnel | 1 | 2007 | 3210 | 0.120 |
Why?
|
Age of Onset | 1 | 2020 | 3266 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1526 | 0.120 |
Why?
|
Biomedical Research | 1 | 2009 | 3306 | 0.110 |
Why?
|
Principal Component Analysis | 1 | 2016 | 939 | 0.110 |
Why?
|
Aged | 8 | 2023 | 162944 | 0.110 |
Why?
|
Markov Chains | 1 | 2016 | 969 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1255 | 0.110 |
Why?
|
Alcoholism | 2 | 2016 | 1904 | 0.110 |
Why?
|
Signal Transduction | 2 | 2013 | 23387 | 0.110 |
Why?
|
Myeloproliferative Disorders | 1 | 2018 | 603 | 0.100 |
Why?
|
Ethics, Business | 1 | 2011 | 8 | 0.100 |
Why?
|
Databases, Genetic | 1 | 2019 | 1780 | 0.100 |
Why?
|
Chromatin | 1 | 2023 | 2917 | 0.100 |
Why?
|
Sex Distribution | 1 | 2017 | 2295 | 0.100 |
Why?
|
Peer Review, Research | 1 | 2014 | 329 | 0.100 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1254 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2013 | 731 | 0.100 |
Why?
|
Logistic Models | 2 | 2016 | 13403 | 0.100 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2013 | 282 | 0.090 |
Why?
|
Age Distribution | 1 | 2017 | 2900 | 0.090 |
Why?
|
Antisocial Personality Disorder | 1 | 2011 | 227 | 0.090 |
Why?
|
Central Nervous System Depressants | 1 | 2011 | 167 | 0.090 |
Why?
|
Databases, Bibliographic | 1 | 2010 | 128 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2019 | 2556 | 0.090 |
Why?
|
Interviews as Topic | 1 | 2017 | 2536 | 0.090 |
Why?
|
Mental Recall | 1 | 2015 | 1205 | 0.080 |
Why?
|
Vitamins | 1 | 2017 | 1608 | 0.080 |
Why?
|
Heroin Dependence | 1 | 2009 | 175 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4553 | 0.080 |
Why?
|
Program Development | 1 | 2014 | 1314 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1058 | 0.080 |
Why?
|
RNA, Small Interfering | 2 | 2016 | 3504 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3800 | 0.070 |
Why?
|
Cell Death | 3 | 2022 | 1695 | 0.070 |
Why?
|
Employment | 1 | 2014 | 1124 | 0.070 |
Why?
|
Risk Factors | 3 | 2022 | 72145 | 0.070 |
Why?
|
Genetic Enhancement | 1 | 2006 | 18 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3388 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2022 | 9639 | 0.070 |
Why?
|
Research Support as Topic | 1 | 2011 | 704 | 0.070 |
Why?
|
Genomics | 2 | 2019 | 5692 | 0.070 |
Why?
|
Neuraminidase | 1 | 2006 | 210 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2485 | 0.070 |
Why?
|
N-Acetylneuraminic Acid | 1 | 2006 | 177 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5948 | 0.070 |
Why?
|
Commerce | 1 | 2011 | 591 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 24913 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3691 | 0.070 |
Why?
|
Personal Autonomy | 1 | 2007 | 297 | 0.060 |
Why?
|
Injections, Intravenous | 1 | 2007 | 1420 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1581 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9185 | 0.060 |
Why?
|
Social Environment | 1 | 2010 | 1023 | 0.060 |
Why?
|
Smoking | 1 | 2022 | 8969 | 0.060 |
Why?
|
Ligands | 2 | 2023 | 3293 | 0.060 |
Why?
|
Ethanol | 1 | 2011 | 1337 | 0.060 |
Why?
|
Mice, Inbred C57BL | 4 | 2019 | 21821 | 0.060 |
Why?
|
Hedgehog Proteins | 1 | 2009 | 781 | 0.060 |
Why?
|
Stem Cells | 1 | 2017 | 3563 | 0.060 |
Why?
|
Transcription Factors | 1 | 2023 | 12164 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4414 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5163 | 0.060 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2023 | 186 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7770 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2019 | 14554 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12242 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10392 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4440 | 0.050 |
Why?
|
Demography | 1 | 2007 | 1650 | 0.050 |
Why?
|
Pilot Projects | 2 | 2022 | 8297 | 0.050 |
Why?
|
Choice Behavior | 1 | 2007 | 802 | 0.050 |
Why?
|
Ubiquitins | 1 | 2023 | 383 | 0.050 |
Why?
|
Research | 1 | 2010 | 1999 | 0.050 |
Why?
|
Genes, p53 | 1 | 2022 | 755 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 18112 | 0.050 |
Why?
|
Mental Health | 1 | 2014 | 2997 | 0.040 |
Why?
|
Brain Stem Neoplasms | 1 | 2022 | 204 | 0.040 |
Why?
|
Solvents | 1 | 2020 | 302 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2015 | 13921 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 799 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15194 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 380 | 0.040 |
Why?
|
Adenosine Triphosphatases | 1 | 2023 | 836 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 53187 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 867 | 0.040 |
Why?
|
Synthetic Biology | 1 | 2020 | 179 | 0.040 |
Why?
|
Glycoproteins | 1 | 2006 | 2260 | 0.040 |
Why?
|
Public Health | 1 | 2011 | 2594 | 0.040 |
Why?
|
Cell Line, Tumor | 4 | 2018 | 16665 | 0.040 |
Why?
|
Patient Selection | 1 | 2010 | 4214 | 0.040 |
Why?
|
K562 Cells | 1 | 2019 | 632 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 77098 | 0.040 |
Why?
|
Inflammasomes | 1 | 2022 | 493 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 284 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2007 | 1952 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2007 | 2275 | 0.040 |
Why?
|
Cryoelectron Microscopy | 1 | 2020 | 573 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2022 | 972 | 0.040 |
Why?
|
Uric Acid | 1 | 2022 | 760 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2022 | 2236 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3391 | 0.040 |
Why?
|
Genes, Dominant | 1 | 2019 | 880 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15530 | 0.030 |
Why?
|
Ubiquitination | 1 | 2020 | 1011 | 0.030 |
Why?
|
Health Behavior | 1 | 2007 | 2630 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1707 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2019 | 1802 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 40054 | 0.030 |
Why?
|
Ribosomal Protein S6 | 1 | 2014 | 70 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1333 | 0.030 |
Why?
|
DNA Repair | 1 | 2023 | 2042 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2022 | 3471 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2007 | 3839 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7645 | 0.030 |
Why?
|
Lovastatin | 1 | 2013 | 120 | 0.030 |
Why?
|
Ontario | 1 | 2014 | 381 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2016 | 808 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 3915 | 0.030 |
Why?
|
Tyrphostins | 1 | 2012 | 67 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2022 | 4200 | 0.030 |
Why?
|
New South Wales | 1 | 2011 | 66 | 0.030 |
Why?
|
Blast Crisis | 1 | 2012 | 103 | 0.030 |
Why?
|
Incidence | 1 | 2010 | 20928 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2012 | 247 | 0.020 |
Why?
|
Serpins | 1 | 2012 | 247 | 0.020 |
Why?
|
Models, Molecular | 1 | 2020 | 5454 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13655 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2007 | 5133 | 0.020 |
Why?
|
Financial Support | 1 | 2011 | 115 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3639 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2022 | 18006 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2012 | 651 | 0.020 |
Why?
|
Child | 2 | 2022 | 77478 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2014 | 721 | 0.020 |
Why?
|
Survival Rate | 1 | 2022 | 12773 | 0.020 |
Why?
|
Obesity | 1 | 2010 | 12705 | 0.020 |
Why?
|
Gene Silencing | 1 | 2014 | 1538 | 0.020 |
Why?
|
Adult Stem Cells | 1 | 2009 | 216 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5851 | 0.020 |
Why?
|
Lung | 1 | 2023 | 9826 | 0.020 |
Why?
|
Cricetulus | 1 | 2006 | 817 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 12946 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2016 | 2623 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2009 | 1274 | 0.010 |
Why?
|
CHO Cells | 1 | 2006 | 1407 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9410 | 0.010 |
Why?
|
Protein Engineering | 1 | 2006 | 541 | 0.010 |
Why?
|
Cricetinae | 1 | 2006 | 2471 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5872 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11472 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2009 | 1221 | 0.010 |
Why?
|
Prognosis | 1 | 2022 | 29010 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39004 | 0.010 |
Why?
|
Infant | 1 | 2022 | 35070 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 40955 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3239 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 7716 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5522 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10472 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2014 | 62966 | 0.000 |
Why?
|